TABLE 2.

Summary estimates for efficacy and acceptability in meta‐analysis of direct comparisons between CGRP antagonists or placebo

Comparisons	BI 44370 TA versus Placebo	MK‐3207 versus Placebo	Olcegepant versus Placebo	Rimegepant versus Placebo	Telcagepant versus Placebo	Ubrogepant versus Placebo
Pain freedom 2 hr postdose	4.03 [1.51, 10.75]	3.65 [1.89, 7.04]	31.11 [3.80, 254.98]	2.11 [1.72, 2.58]	2.64 [2.20, 3.17]	1.85 [1.49, 2.28]
Nausea freedom 2 hr postdose	2.75 [1.39, 5.47]	1.44 [0.90, 2.29]	Missing	1.36 [1.14, 1.62]	1.67 [1.47, 1.90]	1.24 [1.06, 1.46]
Phonophobia freedom 2 hr postdose	2.41 [1.23, 4.72]	1.78 [1.13, 2.81]	Missing	1.84 [1.41, 2.39] a	1.75 [1.54, 1.98]	1.44 [1.24, 1.68]
Photophobia freedom 2 hr postdose	2.62 [1.33, 5.17]	1.64 [1.04, 2.59]	Missing	1.84 [1.56, 2.19]	1.83 [1.49, 2.24] a	1.57 [1.23, 2.00] a
Any adverse events	0.95 [0.32, 2.88]	1.50 [0.89, 2.51]	2.40 [0.70, 8.22]	1.27 [1.01, 1.60]	1.17 [1.02, 1.33]	1.03 [0.83, 1.28]
Treatment‐related adverse events	0.96 [0.06, 15.62]	1.44 [0.72, 2.87]	Missing	1.35 [0.86, 2.11]	1.35 [0.83, 2.18]	1.08 [0.84, 1.40]
Abnormal liver function	Not estimable	Not estimable	Not estimable	1.05 [0.50, 2.19]	1.08 [0.07, 17.45]	2.05 [0.52, 8.14]
Chest discomfort	Missing	Missing	Missing	Not estimable	2.43 [0.41, 14.37]	2.57 [0.13, 50.09]

Values in bold means significant difference.

^a I ² > 50%, and random‐effect model was utilized to estimate effect magnitude.